Introduction:
This quiz collection on food-effect and pharmacokinetic (PK) studies is designed specifically for M.Pharm students preparing for clinical research and regulatory topics. The questions emphasise core concepts such as fed versus fasted study designs, regulatory expectations (FDA/EMA), bioavailability metrics (Cmax, AUC, Tmax), study designs (crossover, washout), impact of food composition (high‑fat meals), biopharmaceutics classification, statistical acceptance criteria, and practical considerations like sample size and special populations. Each MCQ targets applied understanding needed for designing, interpreting, and regulating food‑effect and PK studies, helping students build the competence required for advanced coursework and industry roles.
Q1. What is the primary objective of a food-effect pharmacokinetic study?
- To evaluate the stability of a drug formulation under different storage conditions
- To assess the impact of food on the rate and extent of drug absorption
- To compare the safety profile of the drug in animals and humans
- To determine the maximum tolerated dose in healthy volunteers
Correct Answer: To assess the impact of food on the rate and extent of drug absorption
Q2. Which PK parameters are primarily used to quantify food effects on systemic exposure?
- Half‑life (t1/2) and volume of distribution (Vd)
- Cmax and AUC
- Clearance (CL) and Tmax
- Bioavailability and bioequivalence limits only
Correct Answer: Cmax and AUC
Q3. According to regulatory guidance, what is the typical meal composition recommended for assessing food effect in a fasting vs fed study?
- Low‑fat, high‑protein meal
- Standardised high‑fat, high‑calorie meal
- Only a carbohydrate snack under 200 kcal
- Randomly selected restaurant meal
Correct Answer: Standardised high‑fat, high‑calorie meal
Q4. Which study design is most commonly used for food‑effect bioavailability studies in healthy volunteers?
- Parallel group, single dose
- Two‑period, two‑treatment crossover
- Open‑label, uncontrolled multiple ascending dose
- Factorial design with more than four arms
Correct Answer: Two‑period, two‑treatment crossover
Q5. What is the main reason for including an adequate washout period between periods in a crossover food‑effect study?
- To allow subjects to change dietary habits
- To prevent carryover effects due to residual drug
- To reduce the cost of the study
- To increase the number of samples per period
Correct Answer: To prevent carryover effects due to residual drug
Q6. Which statistical acceptance range is commonly used to evaluate equivalence for AUC and Cmax in bioequivalence and many food‑effect comparisons?
- 50%–150%
- 80%–125%
- 90%–110%
- 70%–130%
Correct Answer: 80%–125%
Q7. How does a high‑fat meal commonly affect the Tmax of a lipophilic, orally absorbed drug?
- Tmax is usually shortened (earlier)
- Tmax is usually prolonged (delayed)
- Tmax remains unchanged for all drugs
- Tmax becomes irrelevant in fed studies
Correct Answer: Tmax is usually prolonged (delayed)
Q8. Which biopharmaceutics property often predicts a negligible food effect on oral absorption?
- High permeability and high solubility (BCS Class I)
- Poor permeability and poor solubility (BCS Class IV)
- High protein binding in plasma
- Extensive first‑pass metabolism in liver
Correct Answer: High permeability and high solubility (BCS Class I)
Q9. When a drug shows significantly higher AUC and Cmax under fed conditions, what regulatory action is typically considered?
- Change in maximum tolerated dose only
- Label recommendation to take with food or fasting depending on safety/efficacy
- No action required if Tmax changes
- Immediate withdrawal of the application
Correct Answer: Label recommendation to take with food or fasting depending on safety/efficacy
Q10. Which population is most commonly used for pivotal food‑effect PK studies required by regulators?
- Patients with the target disease
- Healthy adult volunteers
- Geriatric patients only
- Paediatric subjects
Correct Answer: Healthy adult volunteers
Q11. What is the purpose of performing a pilot or exploratory food‑effect study before pivotal trials?
- To replace the need for pivotal bioequivalence studies
- To characterise the direction and magnitude of food effect and inform pivotal study design
- To determine drug stability under extreme temperatures
- To recruit a larger patient population for safety analysis
Correct Answer: To characterise the direction and magnitude of food effect and inform pivotal study design
Q12. Which non‑compartmental PK parameter calculation is least affected by the sampling schedule under fed vs fasted conditions?
- Tmax
- Cmax
- AUC to last measurable concentration (AUC0‑t) if sampling is adequate
- Apparent clearance (CL/F) when absolute bioavailability is unknown
Correct Answer: AUC to last measurable concentration (AUC0‑t) if sampling is adequate
Q13. Which mechanism can explain an increased oral bioavailability in the fed state for a poorly soluble lipophilic drug?
- Delayed gastric emptying decreasing dissolution
- Enhanced solubilisation by bile salts and lipids in the meal
- Reduced intestinal blood flow
- Increased renal excretion due to food
Correct Answer: Enhanced solubilisation by bile salts and lipids in the meal
Q14. In crossover food‑effect studies, which analysis approach accounts for within‑subject variability?
- Between‑subjects ANOVA only
- Mixed‑effects model or ANOVA with subject nested within sequence
- Simple t‑test ignoring period effects
- Descriptive statistics without inferential testing
Correct Answer: Mixed‑effects model or ANOVA with subject nested within sequence
Q15. Which factor can produce a food‑related decrease in Cmax without changing AUC significantly?
- Food increases fraction absorbed (F)
- Food delays absorption (slower rate) but extent remains similar
- Food enhances first‑pass metabolism
- Food increases renal clearance rapidly
Correct Answer: Food delays absorption (slower rate) but extent remains similar
Q16. When is a separate bioequivalence study under fed conditions mandated for immediate‑release products?
- Only when the drug is BCS Class I
- When food is expected to alter exposure based on physicochemical properties or clinical relevance
- Never; fasting studies are always sufficient
- Only for parenteral formulations
Correct Answer: When food is expected to alter exposure based on physicochemical properties or clinical relevance
Q17. Which of the following best describes a scenario where no clinically meaningful food effect exists?
- AUC and Cmax both change by more than 150% in fed state
- AUC and Cmax remain within regulatory equivalence limits (80%–125%) between fed and fasted
- Only Tmax changes but AUC is unmeasurable
- Cmax decreases by 40% while AUC increases by 90%
Correct Answer: AUC and Cmax remain within regulatory equivalence limits (80%–125%) between fed and fasted
Q18. Which special population may require dedicated food‑effect studies due to altered physiology?
- Young healthy adults with normal GI function
- Patients with gastroparesis or significant GI surgery
- Subjects taking only topical medications
- Subjects with normal renal function only
Correct Answer: Patients with gastroparesis or significant GI surgery
Q19. What role does the Biopharmaceutics Classification System (BCS) play in regulatory decisions about food‑effect studies?
- BCS class alone determines the need for clinical safety studies
- BCS helps predict likelihood of food effect and can inform waiver decisions for in vivo studies in some cases
- BCS is irrelevant for oral drug development
- BCS only guides parenteral formulation selection
Correct Answer: BCS helps predict likelihood of food effect and can inform waiver decisions for in vivo studies in some cases
Q20. Which practical consideration is important when selecting sampling times for a fed vs fasted PK study?
- Use identical sparse sampling for all drugs regardless of Tmax
- Include frequent early sampling and extend sampling period to capture delayed Tmax and terminal phase
- Only measure trough concentrations
- Sampling times are unnecessary if AUC is estimated by modeling only
Correct Answer: Include frequent early sampling and extend sampling period to capture delayed Tmax and terminal phase
